Search Within

Amber Courtney King

Formats
  1. Meeting Abstract (14)
  2. Journal Article (11)
  3. Review (4)
  4. Research Letter (3)
Groups
  1. Adult Leukemia (27)
  2. Center for Hematologic Malignancies (27)
  3. Department of Medicine (27)
  4. Hematologic Malignancies, Division of (27)
  5. Hematology-Oncology Fellows (19)
  6. Weinberg Fellows (17)

More Groups

People
  1. Jae Park (11)
  2. Martin Tallman (11)
  3. Mark Geyer (10)
  4. Andriy Derkach (7)
  5. Eytan Stein (7)
  6. Troy Horvat (7)

More People

Years
  1. 2023 (1)
  2. 2022 (5)
  3. 2021 (3)
  4. 2020 (5)
  5. 2019 (10)
  6. 2018 (3)

More Years

Publications
  1. Blood (14)
  2. Leukemia Research (4)
  3. Annals of Pharmacotherapy (3)
  4. Leukemia and Lymphoma (3)
  5. Blood Advances (2)
  6. Journal of the Advanced Practitioner in Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Elsevier Ltd (4)
  3. Sage Publications (3)
  4. Taylor & Francis Group (3)
  5. Harborside Press (2)
  6. American Association for Cancer Research (1)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of blinatumomab and concurrent oral tyrosine kinase inhibitor therapy as consolidation and maintenance therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia following chemotherapy-sparing induction
    Meeting Abstract

    Geyer, M. B.; King, A. C.; O'Brien, J. C.; Park, J. H.
    Blood (2020)

    Fulltext@MSK | Save
  • Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy
    Journal Article

    Mato, A. R.; Roeker, L. E.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D.; Shadman, M.; Ujjani, C. S.; Yazdy, M. S.; Perini, G. F.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: A dual-center, propensity score-matched analysis
    Journal Article

    Tremblay, D.; King, A.; Li, L.; Moshier, E.; Coltoff, A.; Koshy, A.; Kremyanskaya, M.; Hoffman, R.; Mauro, M. J.; Rampal, R. K.; more...
    Leukemia and Lymphoma (2020)

    Fulltext@MSK | Save
  • Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss
    Meeting Abstract

    Yang, X.; King, A. C.; Kabel, C. C.; Forlenza, C. J.; Park, J. H.; Geyer, M. B.
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: A phase II study
    Meeting Abstract

    Rampal, R. K.; Verstovsek, S.; Devlin, S. M.; King, A. C.; Stein, E. M.; Pemmaraju, N.; Mauro, M. J.; Kadia, T. M.; Montalban-Bravo, G.; Alvarez, K.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Evaluation of biomarkers as predictors of blinatumomab toxicity and real-world management of blinatumomab toxicity in B-acute lymphoblastic leukemia patients
    Meeting Abstract

    King, A. C.; Park, J. H.; Geyer, M. B.
    Blood (2019)

    Fulltext@MSK | Save
  • Real world chart review of blinatumomab to treat patients with high disease burden of relapsed or refractory B-cell precursor acute lymphoblastic leukemia
    Meeting Abstract

    King, A. C.; Bolanos, R.; Velasco, K.; Tu, H.; Zaman, F.; Geyer, M. B.; Park, J. H.
    Blood (2019)

    Fulltext@MSK | Save
  • Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies
    Meeting Abstract

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Jacobs, R.; Hill, B. T.; Lamanna, N.; Brander, D. M.; Shadman, M.; Ujjani, C.; Yazdy, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Axicabtagene ciloleucel: The first FDA-approved CAR T-cell therapy for relapsed/refractory large B-cell lymphoma
    Review

    King, A. C.; Orozco, J. S.
    Journal of the Advanced Practitioner in Oncology (2019)

    Fulltext@MSK | Save